Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.

Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MK, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, Doranz BJ, Crowe JE Jr, Fremont DH, Rossmann MG, Diamond MS.

Cell. 2015 Nov 19;163(5):1095-107. doi: 10.1016/j.cell.2015.10.050. Epub 2015 Nov 6.

PMID:
26553503
2.

Kinetic characterization of trans-proteolytic activity of Chikungunya virus capsid protease and development of a FRET-based HTS assay.

Aggarwal M, Sharma R, Kumar P, Parida M, Tomar S.

Sci Rep. 2015 Oct 6;5:14753. doi: 10.1038/srep14753.

3.

Nonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model).

Broeckel R, Haese N, Messaoudi I, Streblow DN.

Pathogens. 2015 Sep 16;4(3):662-81. doi: 10.3390/pathogens4030662. Review.

4.

Protective and Pathogenic Responses to Chikungunya Virus Infection.

Long KM, Heise MT.

Curr Trop Med Rep. 2015 Mar;2(1):13-21.

PMID:
26366337
5.

Early Events in Chikungunya Virus Infection-From Virus CellBinding to Membrane Fusion.

van Duijl-Richter MK, Hoornweg TE, Rodenhuis-Zybert IA, Smit JM.

Viruses. 2015 Jul 7;7(7):3647-74. doi: 10.3390/v7072792. Review.

6.

Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS, Crowe JE Jr.

Cell Host Microbe. 2015 Jul 8;18(1):86-95. doi: 10.1016/j.chom.2015.06.009. Erratum in: Cell Host Microbe. 2015 Sep 9;18(3):382. Khomadiak, Solomiia [corrected to Khomandiak, Solomiia].

PMID:
26159721
7.

Persistence of anti-chikungunya virus-specific antibodies in a cohort of patients followed from the acute phase of infection after the 2007 outbreak in Italy.

Pierro A, Rossini G, Gaibani P, Finarelli AC, Moro ML, Landini MP, Sambri V.

New Microbes New Infect. 2015 Apr 15;7:23-5. doi: 10.1016/j.nmni.2015.04.002. eCollection 2015 Sep.

8.

A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.

Weber C, Büchner SM, Schnierle BS.

PLoS Negl Trop Dis. 2015 Apr 23;9(4):e0003684. doi: 10.1371/journal.pntd.0003684. eCollection 2015 Apr.

9.

CD8+ T cells control Ross River virus infection in musculoskeletal tissues of infected mice.

Burrack KS, Montgomery SA, Homann D, Morrison TE.

J Immunol. 2015 Jan 15;194(2):678-89. doi: 10.4049/jimmunol.1401833. Epub 2014 Dec 8.

10.

Neutralization activity of patient sera collected during the 2008-2009 Chikungunya outbreak in Thailand.

Kishishita N, Sasayama M, Takeda N, Sa-Ngasang A, Anuegoonpipat A, Anantapreecha S.

J Clin Microbiol. 2015 Jan;53(1):184-90. doi: 10.1128/JCM.02744-14. Epub 2014 Nov 5.

11.

Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand.

Nitatpattana N, Kanjanopas K, Yoksan S, Satimai W, Vongba N, Langdatsuwan S, Nakgoi K, Ratchakum S, Wauquier N, Souris M, Auewarakul P, Gonzalez JP.

Virol J. 2014 Oct 21;11:183. doi: 10.1186/1743-422X-11-183.

12.

Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.

Fong RH, Banik SS, Mattia K, Barnes T, Tucker D, Liss N, Lu K, Selvarajah S, Srinivasan S, Mabila M, Miller A, Muench MO, Michault A, Rucker JB, Paes C, Simmons G, Kahle KM, Doranz BJ.

J Virol. 2014 Dec;88(24):14364-79. doi: 10.1128/JVI.01943-14. Epub 2014 Oct 1.

13.

Characterization of chikungunya virus-like particles.

Noranate N, Takeda N, Chetanachan P, Sittisaman P, A-Nuegoonpipat A, Anantapreecha S.

PLoS One. 2014 Sep 29;9(9):e108169. doi: 10.1371/journal.pone.0108169. eCollection 2014.

14.

Critical role for bone marrow stromal antigen 2 in acute Chikungunya virus infection.

Mahauad-Fernandez WD, Jones PH, Okeoma CM.

J Gen Virol. 2014 Nov;95(Pt 11):2450-61. doi: 10.1099/vir.0.068643-0. Epub 2014 Jul 22.

15.

Antiviral perspectives for chikungunya virus.

Parashar D, Cherian S.

Biomed Res Int. 2014;2014:631642. doi: 10.1155/2014/631642. Epub 2014 May 15. Review.

16.

Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.

Kam YW, Lee WW, Simarmata D, Le Grand R, Tolou H, Merits A, Roques P, Ng LF.

PLoS One. 2014 Apr 22;9(4):e95647. doi: 10.1371/journal.pone.0095647. eCollection 2014.

17.

DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.

Tretyakova I, Hearn J, Wang E, Weaver S, Pushko P.

J Infect Dis. 2014 Jun 15;209(12):1882-90. doi: 10.1093/infdis/jiu114. Epub 2014 Feb 28.

18.

Approaches to the treatment of disease induced by chikungunya virus.

Bettadapura J, Herrero LJ, Taylor A, Mahalingam S.

Indian J Med Res. 2013 Nov;138(5):762-5. Review.

19.

A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

García-Arriaza J, Cepeda V, Hallengärd D, Sorzano CÓ, Kümmerer BM, Liljeström P, Esteban M.

J Virol. 2014 Mar;88(6):3527-47. doi: 10.1128/JVI.03418-13. Epub 2014 Jan 8.

20.

Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response.

Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, Morrison TE.

J Virol. 2013 Dec;87(24):13878-88. doi: 10.1128/JVI.02666-13. Epub 2013 Oct 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk